{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001085","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.903895+00:00","generated_at":"2026-06-19T19:54:34.389421+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fortress Biotech prices $13.9M registered direct equity offering; warrants tied to subsidiary stakes","bullets":["Issued 16.6M shares at $0.835/share for gross proceeds of ~$13.9M.","Directors and officers purchased ~$3.3M of shares at same price, a premium to last close.","Concurrent private placement grants rights to acquire ~3.5% equity in up to 20 new subsidiaries contingent on future deals.","Contingent subsidiary securities exercisable for 10 years at FMV of subsidiary shares at time of trigger.","Offering expected to close Feb 10, 2023; proceeds for working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001085","json":"https://secwatch.observer/filing/0001558370-23-001085.json","markdown":"https://secwatch.observer/filing/0001558370-23-001085.md","text":"https://secwatch.observer/filing/0001558370-23-001085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023001085/0001558370-23-001085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023001085/fbio-20230207x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T19:54:34.389421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3eb42bf2c56530acd70a1b7ac664658db6d50e1d","claim":"Fortress Biotech, Inc. entered into Securities Purchase Agreement with several institutional and accredited investors (effective 2023-02-07).","evidence_excerpt":"On February 7, 2023, Fortress Biotech, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with each of several institutional and accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell an aggregate of 16,642,894 shares (the “ Shares ”) of common stock of the Company","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023001085/0001558370-23-001085-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"several institutional and accredited investors"},{"label":"Effective","value":"2023-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}